Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2

P. Lissoni, A. Bastone, S. Barni, G. Tancini, M. A. Galli

Research output: Contribution to journalArticlepeer-review


It is known that IL-2 cancer immunotherapy is associated with hypotension. The present study was performed to evaluate the influence of low-dose IL-2 subcutaneous therapy on blood pressure in cancer patients with idiopathic hypertension requiring hypotensive therapy. The study included 12 patients, who received IL-2 at 6 million IU/day for at least 4 weeks. Mean values of both systolic and diastolic pressure significantly decreased under IL-2 therapy, and the hypotensive agents were interrupted within 2 weeks in 10/12 patients. Moreover, 6 of them still showed normal blood pressure values without hypotensive therapy after a median follow-up of 6 months. This preliminary study would suggest that low-dose IL-2 subcutaneous therapy may normalize blood pressure values in cancer patients with idiopathic hypertension.

Original languageEnglish
Pages (from-to)65-66
Number of pages2
JournalJournal of Biological Regulators and Homeostatic Agents
Issue number2
Publication statusPublished - 1994


  • blood pressure
  • hypertension
  • interleukin-2

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Endocrinology
  • Physiology
  • Immunology
  • Medicine (miscellaneous)
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)


Dive into the research topics of 'Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2'. Together they form a unique fingerprint.

Cite this